1. Show article details.

    BRIEF-Bluebird Bio Inc Plans To Reduce And Reshape Its Workforce, Primarily In Europe

    Reuters – 7:39 AM ET 04/20/2021

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - PLANS TO REDUCE AND RESHAPE ITS WORKFORCE, PRIMARILY IN EUROPE. * BLUEBIRD BIO INC (BLUE) - CONTINUES TO WORK WITH REGULATORS TO RESUME ITS CLINICAL STUDIES IN SICKLE CELL DISEASE Source text for Eikon: Further company coverage:

  2. Show article details.

    bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations

    Business Wire – 7:30 AM ET 04/20/2021

    bluebird bio, Inc. announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome in its Phase 1/2 study of LentiGlobin for sickle cell disease, the company’s decision to withdraw ZYNTEGLO™ for transfusion-dependent β-thalassemia from the German market and a targeted reshapi...

  3. Show article details.

    PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

    Business Wire – 7:00 AM ET 04/14/2021

    OXFORD, England & CAMBRIDGE, Mass.

  4. Show article details.

    Bluebird bio sets list price for multiple myeloma therapy at $419,500

    Reuters – 9:53 AM ET 03/29/2021

    Bluebird bio Inc (BLUE) said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co. The U.S. FDA on Friday approved the treatment, Abecma, for adult patients with multiple myeloma after four or more prior lines of therapy.

  5. Show article details.

    U.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy

    Reuters – 12:47 AM ET 03/27/2021

    The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co (BMY) and bluebird bio Inc's multiple myeloma therapy, ide-cel, acquired as part of its $74 billion buyout of Celgene, the drugmakers said in a joint statement late on Friday.

  6. Show article details.

    BRIEF-U.S. FDA Approves Bristol-Myers Squibb Co And bluebird bio Inc's Abecma

    Reuters – 12:17 AM ET 03/27/2021

    * U.S. FOOD AND DRUG ADMINISTRATION APPROVES BRISTOL MYERS SQUIBB'S AND BLUEBIRD BIO'S ABECMA, THE FIRST ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

  7. Show article details.

    U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

    Business Wire – 10:59 PM ET 03/26/2021

    Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1 In the pivotal KarMMa trial, the majority of patients achieved rapid, deep and durable responses1 Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mo...

  8. Show article details.

    bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

    Business Wire – 5:30 AM ET 03/15/2021

    90% of evaluable patients alive and free of major functional disabilities at two years follow-up in Phase 2/3 Starbeam study Patients in long-term follow-up study continue to remain alive and MFD-free through up to nearly seven years of follow-up, suggesting eli-cel stabilizes the progression of disease No reports of graft failure, graft rejection, graft-versus-host disease, replication compet...

  9. Show article details.

    bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program

    Business Wire – 7:00 AM ET 03/10/2021

    Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD. bluebird bio has initiated process with regulators to resume clinical studies. Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST. CAMBRIDGE, Mass.

  10. Show article details.

    bluebird bio to Present at Cowen Health Care Conference

    Business Wire – 8:00 AM ET 02/26/2021

    bluebird bio, Inc. today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.

  11. Show article details.

    The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy

    Business Wire – 5:30 PM ET 02/24/2021

    First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 CAMBRIDGE, Mass. The KarMMa study met its primary endpoint of overall response rate and key secondary endpoint of complete response rate.

  12. Show article details.

    BRIEF-Bluebird Bio Reports Q4 And Full Year 2020 Financial Results

    Reuters – 5:06 PM ET 02/23/2021

    bluebird bio Inc: * BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS. * Q4 REVENUE $10.7 MILLION VERSUS $10 MILLION. * Q4 REVENUE ESTIMATE $15.9 MILLION -- REFINITIV IBES DATA. * QTRLY LOSS PER SHARE $3.01. * Q4 EARNINGS PER SHARE VIEW $-2.92 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  13. Show article details.

    bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

    Business Wire – 4:05 PM ET 02/23/2021

    bluebird bio, Inc. today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.

  14. Show article details.

    bluebird bio to Present at Leerink Global Healthcare Conference

    Business Wire – 4:05 PM ET 02/22/2021

    bluebird bio, Inc. today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET.

  15. Show article details.

    BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.

    PR Newswire – 9:00 AM ET 02/19/2021

    NEW YORK, Feb. 19, 2021 Wolf Haldenstein Adler Freeman & Herz LLP  announces that a announces that a federal securities class action lawsuit has been filed in  the  United States District Court for the Eastern District of New York against  bluebird bio, Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired bluebird securities between May 11, 2020 and No...

  16. Show article details.

    BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021

    PR Newswire – 8:00 AM ET 02/19/2021

    PHILADELPHIA, Feb. 19, 2021  Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. on behalf of investors who purchased bluebird securities between May 11, 2020 and November 4, 2020.

  17. Show article details.

    BRIEF-Bluebird Bio Temporarily Suspends Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For SCD

    Reuters – 7:09 AM ET 02/16/2021

    bluebird bio Inc: * BLUEBIRD BIO ANNOUNCES TEMPORARY SUSPENSION ON PHASE 1/2 AND PHASE 3 STUDIES OF LENTIGLOBIN GENE THERAPY FOR SICKLE CELL DISEASE Source text for Eikon: Further company coverage:

  18. Show article details.

    bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

    Business Wire – 7:00 AM ET 02/16/2021

    bluebird bio, Inc. announced today that the company has placed its Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction of acute myeloid leukemia.

  19. Show article details.

    Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (BLUE)

    GlobeNewswire – 4:05 PM ET 02/15/2021

    Gainey McKenna & Egleston announces that a class action lawsuit has been filed against bluebird bio, Inc. in the United States District Court for the Eastern District of New York on behalf of those who purchased or acquired the securities of bluebird between May 11, 2020 and November 4, 2020, inclusive.

  20. Show article details.

    Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, Inc. and Certain Officers - BLUE

    PR Newswire – 5:53 PM ET 02/12/2021

    NEW YORK, Feb. 12, 2021 Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. and certain of its officers. If you are a shareholder who purchased bluebird securities during the Class Period, you have until April 13, 2021 to ask the Court to appoint you as Lead Plaintiff for the class.

Page:

Today's and Upcoming Events

  • May
    10

    BLUE to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    23

    BLUE announced Q4 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.